Yumanity Therapeutics to Present at Upcoming Virtual Investor Conferences
BOSTON, May 27, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Richard Peters, M.D., Ph.D., President and Chief Executive Officer, will present at the following virtual investor conferences in June.
| Jefferies Virtual Healthcare Conference |
| • Thursday, June 3 |
| • 11:00 AM Eastern Time |
| JMP Securities Life Sciences Conference |
| • Wednesday, June 16 |
| • 2:00 PM Eastern Time |
A live audio webcast of each presentation can be accessed through the Events section of the Company's website at . An archived replay of each webcast will be available on the Company's website following the live presentation.
About Yumanity Therapeutics
Yumanity Therapeutics is a clinical-stage biopharmaceutical company dedicated to accelerating the revolution in the treatment of neurodegenerative diseases through its scientific foundation and drug discovery platform. The Company’s most advanced product candidate, YTX-7739, is currently in Phase 1 clinical development for Parkinson’s disease. Yumanity’s drug discovery platform enables the Company to rapidly screen for potential disease-modifying therapies by overcoming the toxicity of misfolded proteins associated with neurogenerative diseases. Yumanity’s pipeline consists of additional programs focused on Lewy body dementia, multi-system atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease), frontotemporal lobar dementia (FTLD), and Alzheimer’s disease. For more information, please visit .
Investors:
Burns McClellan, Inc.
Lee Roth
(212) 213-0006
Media:
Burns McClellan, Inc.
Ryo Imai / Robert Flamm, Ph.D.
/
(212) 213-0006
